Healio: Top in Cardiology: Exercise Lowers Cardiac Arrest Risk, CV Benefits of Semaglutide

Twenty minutes of vigorous physical activity per week was associated with a lower risk for cardiac arrest, according to a European study.

In another top story, Mikhail Kosiborod, MD, FACC, FAHA, vice president of research at Saint Luke’s Health System and professor of medicine at the University of Missouri-Kansas City School of Medicine, reviewed research at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on the cardiovascular benefits of Ozempic/Wegovy (semaglutide, Novo Nordisk) for adults with obesity.

“There are two landmark trials heralding a complete paradigm shift in targeting obesity as a highly effective strategy in [heart failure with preserved ejection fraction] and atherosclerotic CVD,” Kosiborod said. “I think we’re going to see a lot more in the coming years that’s really going to change practice.”

Read the full Healio article: Top in Cardiology: Exercise Lowers Cardiac Arrest Risk, CV Benefits of Semaglutide

Related Content

Dec. 20, 2023

Kansas City Business Journal: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'
A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.
Dec. 18, 2023

Healio: Targeting Obesity may be ‘Highly Effective Strategy’ for Treating HFpEF, ASCVD
Dr. Kosiborod presented the main results of STEP-HFpEF trial during the opening late breaking clinical trial session at the European Society of Cardiology Congress (ESC Congress)—the world’s largest cardiology conference.
Oct. 25, 2023

New York Times: Even Short Runs Have Major Health Benefits
Dr. James O'Keefe explains why even short runs have major health benefits.